Jeremy Williams, MD
Family Medicine · Weston, WVNPI 1922212117
Payments from drug & device makers
Across 700 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Amgen$1K
- Lilly USA, LLC$840
- Merck$626
- Novo Nordisk$607
- plus $4K from 21 others
What the payments were for
- Food & beverage$10,075100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 92 | $1,596 |
| AbbVie(2 entities) | 104 | $1,472 |
| Amgen | 81 | $1,158 |
| Lilly USA, LLC | 65 | $840 |
| Merck | 51 | $626 |
| Novo Nordisk | 45 | $607 |
| Boehringer Ingelheim | 40 | $557 |
| Astellas Pharma US Inc | 35 | $507 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $506 |
| GSK | 36 | $481 |
| Bayer | 23 | $354 |
| Sanofi-aventis U.S. LLC | 21 | $284 |
| Exact Sciences | 16 | $237 |
| Pfizer | 14 | $215 |
| Mentor Worldwide LLC | 5 | $172 |
| Amarin Pharma, Inc. | 7 | $95 |
| Daiichi Sankyo Inc. | 6 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $69 |
| Novartis | 4 | $63 |
| Sanofi Pasteur Inc. | 3 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$10,098 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 163 | $137,484 |
| TrulicityDulaglutide | 62 | $95,359 |
| OzempicSemaglutide | 71 | $90,642 |
| EliquisApixaban | 112 | $89,611 |
| MounjaroTirzepatide | 72 | $76,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $40,385 |
| JanuviaSitagliptin Phosphate | 66 | $33,227 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $31,288 |
| LinzessLinaclotide | 49 | $30,464 |
| Risperdal ConstaRisperidone Microspheres | 22 | $27,949 |
| FarxigaDapagliflozin Propanediol | 55 | $27,913 |
| XareltoRivaroxaban | 34 | $20,553 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,405 |
| Repatha SureclickEvolocumab | 16 | $17,241 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $840 | $171,900134 claims |
| Boehringer IngelheimJardiance, Tradjenta | $557 | $152,797202 claims |
| Novo NordiskOzempic | $607 | $90,64271 claims |
| PfizerEliquis | $215 | $89,611112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,596 | $60,482122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $481 | $54,15374 claims |
| MerckJanuvia | $626 | $33,22766 claims |
| AbbVieLinzess | $1,472 | $30,46449 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $506 | $10,43219 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $284 | $9,67151 claims |
| Astellas Pharma US IncMyrbetriq | $507 | $9,42436 claims |
| NovartisEntresto | $63 | $8,95822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Weston
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.